The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan

BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are the standard first-line treatment for patients with advanced and recurrent EGFR-positive non-small cell lung cancer. OBJECTIVE: The main objective of the present study was to compare the clinical efficacies between os...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yen-Hsiang, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Yang, Tsung-Ying, Chen, Kun-Chieh, Su, Kang-Yi, Yu, Sung-Liang, Chen, Jeremy J. W., Chang, Gee-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633524/
https://www.ncbi.nlm.nih.gov/pubmed/35460474
http://dx.doi.org/10.1007/s11523-022-00878-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633524/
https://www.ncbi.nlm.nih.gov/pubmed/35460474
http://dx.doi.org/10.1007/s11523-022-00878-x

Ejemplares similares